Edition:
India

Coherus BioSciences Inc (CHRS.OQ)

CHRS.OQ on NASDAQ Stock Exchange Global Market

19.63USD
7 Aug 2020
Change (% chg)

$2.22 (+12.75%)
Prev Close
$17.41
Open
$19.95
Day's High
$20.72
Day's Low
$18.47
Volume
1,061,559
Avg. Vol
588,144
52-wk High
$23.88
52-wk Low
$10.89

Summary

Name Age Since Current Position

Dennis Lanfear

64 2016 Chairman of the Board, President, Chief Executive Officer

Jean-Frederic Viret

54 2014 Chief Financial Officer

Vincent Anicetti

65 2018 Chief Operating Officer

Vladimir Vexler

62 2018 Chief Scientific Officer

Thomas Fitzpatrick

2019 Chief Legal Officer

Mats Wahlstrom

66 2012 Lead Independent Director

Christos Richards

62 2011 Director

Kimberly Tzoumakas

52 2020 Director

James Healy

55 2014 Independent Director

V. Bryan Lawlis

68 2014 Independent Director

Samuel Nussbaum

71 2018 Independent Director

Ali Satvat

42 2014 Independent Director

Mary Szela

57 2014 Independent Director

Biographies

Name Description

Dennis Lanfear

Mr. Dennis M. Lanfear serves as Chairman of the Board, President, Chief Executive Officer of the Company. He is our co-founder and has served as our President and Chief Executive Officer and as a member of our Board of Directors since our inception in September 2010. Mr. Lanfear previously was President of InteKrin Therapeutics Inc., a biopharmaceutical company, from 2005 to May 2010. Prior to that, Mr. Lanfear served in various senior leadership roles at Amgen Inc., a biopharmaceutical company from 1986 to 1999. While at Amgen, Mr. Lanfear had key leadership positions in the Process Development department, which under his management became an area of key strategic advantage for Amgen. Mr. Lanfear has also held senior leadership roles in several product development programs including those for growth factors, somatotrophins and neurotrophins and directed efforts from preclinical studies to Phase 3 clinical trials at Amgen. Mr. Lanfear holds B.S. degrees in Chemical Engineering and Biochemistry from Michigan State University and an M.B.A. from the Anderson School of Management at the University of California, Los Angeles. We believe Mr. Lanfear is qualified to serve on our Board of Directors because of his background and various leadership roles in the biopharmaceutical field.

Jean-Frederic Viret

Dr. Jean-Frederic Viret Ph.D. serves as Chief Financial Officer of the Company. He has served as the Company’s Chief Financial Officer since September 2014. Previously, Dr. Viret was Chief Financial Officer at diaDexus, Inc., a cardiovascular diagnostics company, from February 2012 to September 2014. diaDexus, Inc. filed a voluntary petition for bankruptcy in June 2016. Prior to that, Dr. Viret was Chief Financial Officer at XDx, Inc. (now CareDx, Inc.), a privately held molecular diagnostics company, from December 2009 to January 2012. From March 2009 to December 2009, Dr. Viret served as the President of JV Consulting, a private consulting firm that provided accounting, public company compliance and other financial consulting services to technology companies. Prior to that time, Dr. Viret served in various capacities at Anesiva, Inc. (previously known as Corgentech Inc.), a public biopharmaceutical company, most recently as a finance consultant from February 2009 to May 2009. Dr. Viret served as Anesiva’s Vice President and Chief Financial Officer from March 2008 to February 2009 and as its Vice President, Finance from August 2006 to February 2008. Dr. Viret held various positions in finance in Anesiva from December 2002 to August 2006 and at Tularik Inc. from March 2000 to November 2002. He held various positions in the business assurance services of PricewaterhouseCoopers LLP from September 1997 to March 2000. Dr. Viret has also served on the Board of Directors of RubrYc Therapeutics, Inc. since October 2018. Dr. Viret received a B.S. in Engineering from the Institut National Polytechnique de Lorraine, an M.B.A. from Cornell University and a Ph.D. in Plant Molecular Biology from Université Louis Pasteur (Strasbourg I). He was a visiting fellow at Harvard University and a postdoctoral fellow at the Massachusetts Institute of Technology.

Vincent Anicetti

Mr. Vincent R. Anicetti serves as Chief Operating Officer of the Company. He has served as our Chief Operating Officer since May 2018, served as our Chief, Quality and Compliance Officer from March 2018 to May 2018 and served as our Executive Vice President of Quality and Compliance from June 2014 to March 2018. Mr. Anicetti previously served as Executive Director of Quality of Boehringer Ingelheim, a pharmaceutical company, from February 2013 to May 2014. Prior to that, from June 2006 to September 2011, Mr. Anicetti served as Vice President of Biologics Quality at Genentech, a biotechnology corporation. Prior to that, Mr. Anicetti served as Vice President of Portfolio Management and Senior Director of Regulatory Affairs at Genentech. Since August 2011, Mr. Anicetti is also an Industry Professor at the Keck Graduate Institute, a private graduate school. Mr. Anicetti has a M.S. in Biological Sciences from San Francisco State University and currently serves on the board of directors of the San Francisco State University Foundation in San Francisco, California. 24

Vladimir Vexler

Dr. Vladimir Vexler Ph.D is Chief Scientific Officer of the company. Dr. Vexler serves as our Chief Scientific Officer and served as Executive Vice President of Analytical and Translational Sciences since April 2017. Dr. Vexler served as our Senior Vice President of Translational & Development Sciences since June 2016, and our Vice President, Preclinical Development since January 2013. Prior to that, Dr. Vexler was a Senior Research Leader, Biotherapeutics at Hoffman-La Roche, where he acted as Global scientific leader for nonclinical safety of biotherapeutics and chaired Roche pRED Global Biotherapeutics Safety Team since December 2009. Dr. Vexler began his career as a post-doctoral fellow at the Department of Radiology at UCSF. Dr. Vexler received his M.A. in Chemistry from Lomonosov Moscow State University and his Ph.D. from the Institute of Chemical Physics, Academy of Science, Moscow.

Thomas Fitzpatrick

Mr. Thomas Fitzpatrick serves as Chief Legal Officer of the Company. Mr. Fitzpatrick brings more than 20 years of executive-level legal experience to his role as leader of Coherus' legal and compliance departments, reporting directly to Coherus President and CEO, Denny Lanfear. Mr. Fitzpatrick will serve as a member of the Company's executive leadership team and be involved in all legal matters. Prior to Coherus, Fitzpatrick was an equity partner in Thomas Fitzpatrick national and international law firms representing technology and life science companies. Earlier in his career, Fitzpatrick was a Deputy District Attorney in San Mateo, California. He earned his Juris Doctor from Santa Clara University School of Law and a Bachelor of Arts degree from the University of California, Berkeley.

Mats Wahlstrom

Mr. Mats Wahlstrom serves as Lead Independent Director of the Company. He has served as a member of our Board of Directors since January 2012. He currently serves as the Executive Chairman of KMG Capital Partners, LLC, where he has been a senior leader since April 2012, Chairman of Triomed AB since October 2016, Chairman of Surefire Medical, Inc. (DBA TriSalus Life Sciences) since January 2017 and Chairman of Caduceus Medical Holdings, Inc. since August 2010. He has served on the boards of directors of Alteco Medical AB since October 2012, Empirican Group, Inc. since July 2016 and PCI | HealthDev since August 2010. He served as a director of Health Grades, Inc., a Nasdaq-listed healthcare ratings company, from March 2009 through its sale to a private equity firm in October 2010, a director of Getinge AB, a Swedish stock exchange-listed medical device company, from March 2012 to March 2017 and as a director of Zynex Inc., an over-the-counter medical device manufacturer, from October 2010 through January 2014. From January 2004 to December 2009, Mr. Wahlström served as co-CEO of Fresenius Medical Care North America and a member of the management board at Fresenius Medical Care AG & Co. KGaA. From November 2002 to December 2009, he served as President and CEO of Fresenius Medical Services, which operated more than 1,700 dialysis clinics in the U.S. Prior to joining Fresenius Medical Care in 2002, he held various positions at Gambro AB in Sweden, including President of Gambro North America and Chief Executive Officer of Gambro Healthcare Inc. as well as Chief Financial Officer of the Gambro Group. Mr. Wahlström has a B.S. degree in Economics and Business Administration from University of Lund, Sweden. We believe Mr. Wahlström is qualified to serve on our Board of Directors because of his extensive management and director experience in the life sciences and healthcare sectors.

Christos Richards

Mr. Christos Richards is Director of the Coherus BioSciences, Inc. Mr. Richards has served as a member of our Board of Directors since March 2011. Mr. Richards has served as consultant at Spencer Stuart, a global leader in executive search, board services and leadership consulting, since October 2019. Prior to that, he was a partner at Catalyst Advisors, LLC, an executive search firm, from January 2014 to October 2019. From October 1998 to January 2014, Mr. Richards held positions of increasing responsibility at Levin & Company, Inc., an executive search and consulting firm. From January 2009 to January 2014, Mr. Richards served as Chief Executive Officer of Levin & Company, Inc. Mr. Richards served as a Principal of Stanton Chase International from July 1996 to October 1998. From 1987 to July 1996, Mr. Richards founded and served as Chief Executive Officer of Career Connection/Nexium Inc. Mr. Richards was educated in Switzerland and is fluent in German and Swiss German. Mr. Richards brings to the board experience in the recruitment of numerous executive level professionals, including a diverse range of C-level and VP-level executives. We believe Mr. Richards is qualified to serve on our Board of Directors based on his extensive senior management experience and expertise. 7

Kimberly Tzoumakas

Ms. Kimberly J. Tzoumakas serves as Director of the Company. She has served as Chief Executive Officer of 21st Century Oncology, a global provider of integrated cancer care services, since January 2018, transitioning from interim Chief Executive Officer to permanent Chief Executive Officer in April 2018. From November 2014 to January 2018, she served as its General Counsel and as a member of its leadership team. From November 2001 to April 2018, Ms. Tzoumakas practiced health care law with Hall Render Killian Heath & Lyman, providing strategic, transactional and governance advice to health care clients throughout the country. While at Hall Render, she was also a long-term managing partner of the firm’s Michigan office and a board member of the firm. She has also served on the Board of Directors of SeaSpine Holdings Corporation, a publicly-held medical technology company, since February 2019. Ms. Tzoumakas received a B.A. in business administration from Northwood University and a J.D. from the Thomas M. Cooley Law School. Ms. Tzoumakas was selected as a director because of her significant experience and background in the health care sector.

James Healy

Dr. James I. Healy M.D., Ph.D. serves as Independent Director of the Company. He has been a member of our Board of Directors since February 2014. Dr. Healy has been a General Partner of Sofinnova Investments (formerly Sofinnova Ventures, Inc.), a venture capital firm, since June 2000. Prior to this, Dr. Healy held various positions at Sanderling Ventures, Bayer Healthcare Pharmaceuticals (as successor to Miles Laboratories) and ISTA Pharmaceuticals, Inc. Dr. Healy is currently on the board of directors of Ascendis Pharma A/S, NuCana plc, Karuna Therapeutics, Inc., Natera, Inc., ObsEva SA, Y-mAbs Therapeutics, Inc. and two private companies. Previously, he served as a board member of Amarin Corporation, Auris Medical Holding AG, Edge Therapeutics, Inc., Hyperion Therapeutics, Inc., InterMune, Inc., Iterum Therapeutics plc, Anthera Pharmaceuticals, Inc., Durata Therapeutics, Inc., CoTherix, Inc., Movetis NV and several private companies. In 2011, Dr. Healy won the IBF Risk Innovator Award and was named as one of the industry’s top leading Life Science investors in 2013 by Forbes Magazine. Dr. Healy holds an M.D. and a Ph.D. in Immunology from the Stanford University School of Medicine and holds a B.A. in Molecular Biology and a B.A. in Scandinavian Studies from the University of California, Berkeley. He was previously a Director on the Board of the National Venture Capital Association (NVCA) and the Board of the Biotechnology Industry Organization (BIO). We believe Dr. Healy is qualified to serve as a director due to his significant medical background, extensive experience investing and working in the life science industry and his extensive service on the boards of directors of other life sciences companies.

V. Bryan Lawlis

Dr. V. Bryan Lawlis Jr serves as Independent Director of the Company. He has served on our Board of Directors since May 2014 and has also served as the Chairman of our Scientific Advisory Board from November 2012 through June 2016. He currently serves as the Science Director for our Board of Directors. He served as the President and Chief Executive Officer of Itero Biopharmaceuticals, LLC, a privately held limited liability holding company which has held the assets of Itero Biopharmaceuticals, Inc., or Itero Biopharmaceuticals, from August 2011 until its dissolution in 2017. Dr. Lawlis co-founded and served as President and Chief Executive Officer of Itero Biopharmaceuticals, from 2006 until it discontinued operations in August 2011. Prior to that, he served as President and Chief Executive Officer of Aradigm Corporation, a pharmaceutical company, from August 2004, and served on its board of directors from February 2005, continuing in both capacities until August 2006. Dr. Lawlis served as Aradigm Corporation’s President from June 2003 to August 2004 and as its Chief Operating Officer from November 2001 to June 2003. Previously, Dr. Lawlis co-founded Covance Biotechnology Services, Inc., a contract biopharmaceutical manufacturing company, served as its President and Chief Executive Officer from 1996 to 1999, and served as Chairman from 1999 to 2001 when it was sold to Diosyth RTP, Inc., a division of Akzo Nobel, NV. From 1981 to 1996, Dr. Lawlis was employed at Genencor, Inc., a biotechnology company, and Genentech. His last position at Genentech was Vice President of Process Sciences. Dr. Lawlis has served on the boards of directors of three privately held companies, Reform Biologics, LLC since February 2014 and AbSci LLC since April 2016. He has also served on the boards of directors at Sutro Biopharmaceuticals, Inc., a public biopharmaceutical company from July 2003 until June 2020, BioMarin Pharmaceutical Inc., a public biopharmaceutical company since June 2007 and Geron Corporation, a public biopharmaceutic

Samuel Nussbaum

Dr. Samuel R. Nussbaum M.D. serves as Independent Director of the Company. Dr. Nussbaum has served on our Board of Directors since March 2018. Dr. Nussbaum currently serves as a Strategic Consultant to EBG Advisors and a Senior Advisor to Sandbox Industries and to the Ontario Teachers’ Pension Plan. Dr. Nussbaum is a Professor of Clinical Medicine at Washington University School of Medicine, an adjunct professor at the Olin School of Business, Washington University and a Senior Fellow at the USC Schaeffer Center for Health Policy and Economics. From 2000 until 2016, Dr. Nussbaum served as Executive Vice President, Clinical Health Policy, and Chief Medical Officer for Anthem. Dr. Nussbaum received his B.A. from New York University and his M.D. from Mount Sinai School of Medicine. He trained in internal medicine at Stanford University and Massachusetts General Hospital and in endocrinology at Harvard Medical School and Massachusetts General Hospital. We believe Dr. Nussbaum is qualified to serve on our Board of Directors based on his extensive experience in the health care industry.

Ali Satvat

Mr. Ali J. Satvat serves as Independent Director of the Company. Mr. Satvat has served as a member of our Board of Directors since May 2014. Mr. Satvat joined KKR in January 2012 and is a Partner, Co-Head of the Health Care industry team within KKR’s Americas Private Equity platform and Head of KKR Health Care Strategic Growth. Mr. Satvat is a member of the Investment Committee and the Portfolio Management Committee for KKR’s Americas Private Equity platform and chairs the Investment Committee and the Portfolio Management Committee for KKR Health Care Strategic Growth. Mr. Satvat has served as a member of the boards of directors of various private and public companies, including BridgeBio Pharma, Inc. since March 2016, Eidos Therapeutics, Inc. since June 2018 and PRA Health Sciences, Inc. from September 2013 to April 2018. Prior to joining KKR, Mr. Satvat was a Principal with Apax Partners, where he invested in health care from 2006 to 2012. Previously, Mr. Satvat held various positions with Johnson & Johnson Development Corporation, Audax Group and The Blackstone Group. Mr. Satvat holds an A.B. in History and Science from Harvard College and an M.B.A. in Health Care Management and Entrepreneurial Management from the Wharton School of the University of Pennsylvania. Mr. Satvat also serves on the board of directors of the Healthcare Private Equity Association. We believe Mr. Satvat is qualified to serve on our Board of Directors based on his extensive investment experience in the health care industry.

Mary Szela

Ms. Mary T. Szela serves as Independent Director of the Company. She has served as a member of our Board of Directors since July 2014. In January 2018, Ms. Szela was named Chief Executive Officer and President of Surefire Medical, Inc. (TriSalus LifeSciences) and currently serves on its board of directors. Mats L. Wahlström, a member of our Board of Directors, currently serves as Chairman of Surefire Medical, Inc. (TriSalus LifeSciences). From January 2016 to November 2016, Ms. Szela served as Chief Executive Officer of Aegerion Pharmaceuticals, Inc. and served on its board of directors. In November 2016, Aegerion Pharmaceuticals, Inc. merged with QLT Inc. to form Novelion Therapeutics Inc., where, until November 2017, Ms. Szela served as Chief Executive Officer and as a member of its board of directors. Ms. Szela served as the Chief Executive Officer of Melinta Therapeutics, Inc., an antibiotic development company, from April 2013 to August 2015. She has also served on the board of directors of Alimera Sciences, Inc. since June 2018, Kura Oncology, Inc. since October 2018, Melinta from January 2013 to August 2015, Receptos, Inc. from June 2014 to July 2015, Novo Nordisk from March 2014 to March 2017 and Suneva Medical, Inc. from July 2012 to 2017. Previously, Ms. Szela joined Abbott Laboratories in 1987 and held several leadership positions, including Senior Vice President of Global Strategic Marketing from January 2010 to May 2012 and Senior Vice President of U.S. Pharmaceuticals from September 2008 to December 2009. Prior to Abbott, Ms. Szela worked for the University of Illinois Hospital. Ms. Szela earned a B.S. in Nursing and an M.B.A. from the University of Illinois at Chicago. We believe Ms. Szela is qualified to serve on our Board of Directors because of her extensive management experience and expertise in pharmaceutical company operations..

Basic Compensation

Name Fiscal Year Total

Dennis Lanfear

5,361,710

Jean-Frederic Viret

1,829,590

Vincent Anicetti

1,810,840

Vladimir Vexler

1,757,230

Thomas Fitzpatrick

--

Mats Wahlstrom

261,402

Christos Richards

206,402

Kimberly Tzoumakas

--

James Healy

216,402

V. Bryan Lawlis

243,902

Samuel Nussbaum

213,902

Ali Satvat

216,402

Mary Szela

226,402
As Of  31 Dec 2019